Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
Federico Argüelles-AriasF Javier Rodriguez GonzálezJaime González AntuñaLuisa Castro LariaFernando Gutiérrez MartinezGuillermo Alcaín MartinezBelén Maldonado PérezRaquel Camargo CameroJ Victor Martos Van DussenAlejandra Fernández CastañerValdés Delgado TeresaPublished in: Inflammatory bowel diseases (2024)
IV UST maintenance effectively sustained remission in most patients at 52 weeks.
Keyphrases